- AIDS vaccine suffers setback in US. Roberts, John // BMJ: British Medical Journal (International Edition);6/11/94, Vol. 308 Issue 6943, p1527
Reports the HIV infection of seven people involved in early trials of AIDS vaccine in the United States. Influence of gp120 fragment from the outer coat of the virus on the production of antibodies; Study on the safety of the vaccines; Details on the risk of acquiring HIV infection.
- Erratum to: Endorsement of Compulsory HIV Vaccination Policy Among Populations at High Risk of HIV Exposure (LA VOICES). Newman, Peter; Lee, Sung-Jae; Rudy, Ellen; Diamant, Allison; Duan, Naihua; Nakazono, Terry; Cunningham, William // Prevention Science;Jun2014, Vol. 15 Issue 3, p436
A correction to the article "Endorsement of Compulsory HIV Vaccination Policy Among Populations at High Risk of HIV Exposure (LAVOICES)" that was published online in the March 19, 2014 issue is presented.
- Prospects for live attenuated HIV. Desrosiers, Ronald C. // Nature Medicine;Sep98, Vol. 4 Issue 9, p982
Comments on the use of live attenuated HIV-1 strains as a vaccine approach for AIDS. Risks associated with the use of live vaccine strains in clinical trials involving human volunteers; Argument that advancement of life attenuated vaccines should not occur at the expense of other vaccine...
- Use of Adenovirus Serotype 5 Vaccine Vectors in Seropositive, Uncircumcised Men: Safety Lessons from the Step Trial. Richie, Thomas L.; Villasante, Eileen F. // Journal of Infectious Diseases;Feb2013, Vol. 207 Issue 4, p689
A letter to the editor in response to the article "Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrateswaning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine," by A. Duerr, Y. Huang and S. Buchbinder in the...
- Research may lead to new therapeutics against HIV-1. // Infectious Disease News;Apr2014, Vol. 27 Issue 4, p22
The article discusses a study led by Sara Crespillo, first published online on December 3, 2013 in "The Journal of Biological Chemistry," on anti-HIV monoclonal antibodies' roles in binding affinity and implications for the development of new HIV treatments or vaccines.
- Finally, AIDS is on the run. // New Scientist;12/3/2011, Vol. 212 Issue 2841, p3
An introduction is presented in which the editor discusses a report within the issue on HIV vaccine research, arguing that this potential treatment underscores why the global economic recession should not affect funding for HIV/AIDS research programs.
- AIDS confab highlights prevention. Highleyman, Liz // Bay Area Reporter;8/24/2006, Vol. 36 Issue 34, p12
Information about several reports discussed at the XVI International AIDS Conference held in August 2006 in Toronto, Ontario is presented. New methods to prevent HIV infection are strongly being emphasized. The pre-exposure prophylaxis is one of the new technologies being highlighted in the...
- HIV-1 Envelope gp41 Broadly Neutralizing Antibodies: Hurdles for Vaccine Development. Verkoczy, Laurent; Kelsoe, Garnett; Haynes, Barton F. // PLoS Pathogens;May2014, Vol. 10 Issue 5, p1
The authors argue that identifying impediments to broadly neutralizing antibodies (bnAbs) induction to devise better immunization strategies is a central goal for the development of HIV-1 vaccine. They discuss the potential structural and immunological hurdles to bnAbs induction. The evidence...
- Semiparametric estimation of the average causal effect of treatment on an outcome measured after a postrandomization event, with missing outcome data. Gilbert, Peter B.; Yuying Jin // Biostatistics;Jan2010, Vol. 11 Issue 1, p34
In the past decade, several principal stratificationâ€“based statistical methods have been developed for testing and estimation of a treatment effect on an outcome measured after a postrandomization event. Two examples are the evaluation of the effect of a cancer treatment on quality of...
- Enhanced Immunogenicity of HIV-1 Envelope gp140 Proteins Fused to APRIL. Isik, Gözde; Sliepen, Kwinten; van Montfort, Thijs; Sanders, Rogier W. // PLoS ONE;Sep2014, Vol. 9 Issue 9, p1
Current HIV-1 vaccines based on the HIV-1 envelope glycoprotein spike (Env), the only relevant target for broadly neutralizing antibodies, are unable to induce protective immunity. Env immunogenicity can be enhanced by fusion to costimulatory molecules involved in B cell activation, such as...